Axsome Therapeutics Inc (AXSM)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Axsome Therapeutics Inc chart...

About the Company

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.

CEO

Herriot Tabuteau

Exchange

NASDAQ

Website

http://axsome.com/

$M

Total Revenue

353

Employees

$4B

Market Capitalization

-16.92

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AXSM News

What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?

on MSN ago, source:

Axsome Therapeutics Inc (NASDAQ:AXSM) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy ...

What Analysts Are Saying About Axsome Therapeutics Stock

9d ago, source:

Analysts have recently evaluated Axsome Therapeutics and provided 12-month price targets. The average target is $123.46, ...

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

2d ago, source: Zacks.com on MSN

Axsome Therapeutics AXSM announced encouraging data from the phase III SYMPHONY study on its investigational narcolepsy drug AXS-12. The study achieved its primary endpoint of a rapid and significant ...

Axsome's sleep disorder drug succeeds in late-stage trial, shares rise

3d ago, source:

Axsome Therapeutics said on Monday its experimental therapy cut the frequency of disruptive episodes of muscle weakness tied to a sleep disorder called narcolepsy in a late-stage trial.

Optimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite Challenges

1d ago, source:

Leerink Partners analyst Marc Goodman has maintained their bullish stance on AXSM stock, giving a Buy rating yesterday. Marc Goodman has given ...

Axsome Therapeutics’ Small Molecule Clears Phase III Trial in Narcolepsy

2d ago, source: BioSpace

Axsome clinched a late-stage victory for its chronic sleep disorder candidate AXS-12, which demonstrated significant ...

Axsome Therapeutics files patent for microparticles containing bupropion for treating depression

2d ago, source: Pharmaceutical Technology

Discover Axsome Therapeutics' innovative patent for bupropion microparticles, optimized for treating depression. Learn about specific particle size ranges and compositions for enhanced drug delivery.

Axsome Therapeutics announces toplines results from CRESCENDO survey of patients with narcolepsy type 1

1d ago, source: Pharmabiz

Axsome Therapeutics announces toplines results from CRESCENDO survey of patients with narcolepsy type 1: New York Wednesday, March 27, 2024, 17:00 Hrs [IST] Axsome Therapeutics, I ...

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

3d ago, source:

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved ...

Axsome Therapeutics' Phase 3 SYMPHONY Study In Narcolepsy Meets Primary Goal

3d ago, source:

(RTTNews) - Axsome Therapeutics, Inc. (AXSM) Monday said the Phase 3 SYMPHONY study of its drug candidate AXS-12 for the treatment of narcolepsy met its primary goal. Narcolepsy is a brain and nervous ...

Axsome Triumphs Over Major Depressive Disorder With Auvelity

6d ago, source:

Since Auvelity consists of two active ingredients, its mechanism of action is complex and is based on both the inhibition of ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...